Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study.
Quick Facts
What This Study Found
Long-term lanreotide: median PFS 32.8 months from OLE entry for continuous lanreotide patients. Placebo-to-lanreotide crossover patients had 14.0 months PFS.
Key Numbers
Median PFS 32.8 months (continuous); 14.0 months (crossover)
How They Did This
Open-label extension of CLARINET phase 3 trial. All patients received lanreotide 120mg q28d.
Why This Research Matters
Confirms sustained antiproliferative benefit of lanreotide beyond 96 weeks, supporting long-term use.
What This Study Doesn't Tell Us
Open-label, no blinded comparison. Selection bias in extension enrollment.
Trust & Context
- Original Title:
- Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study.
- Published In:
- Endocrine, 71(2), 502-513 (2021)
- Authors:
- Caplin, Martyn E, Ruszniewski, Philippe
- Database ID:
- RPEP-05304
Evidence Hierarchy
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05304APA
Caplin, Martyn E; Pavel, Marianne; Phan, Alexandria T; Cwikla, Jaroslaw B; Sedlackova, Eva; Cadiot, Guillaume; Wolin, Edward M; Capdevila, Jaume; Wall, Lucy; Rindi, Guido; Langley, Alison; Martinez, Santiago; Ruszniewski, Philippe. (2021). Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study.. Endocrine, 71(2), 502-513. https://doi.org/10.1007/s12020-020-02475-2
MLA
Caplin, Martyn E, et al. "Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study.." Endocrine, 2021. https://doi.org/10.1007/s12020-020-02475-2
RethinkPeptides
RethinkPeptides Research Database. "Lanreotide autogel/depot in advanced enteropancreatic neuroe..." RPEP-05304. Retrieved from https://rethinkpeptides.com/research/caplin-2021-lanreotide-autogeldepot-clarinet-ole
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.